Baker McKenzie represented Takeda in its global strategic partnership with Innovent Biologics, bolstering Takeda’s oncology pipeline with next-generation investigational medicines for the treatment of solid tumors.
Under terms of the agreement, Takeda will gain rights to two late-stage oncology assets —IBI363 and IBI343—outside Greater China, and an exclusive option to license an early-stage program. IBI363, a bispecific antibody fusion protein, is being evaluated in lung and colorectal cancers, while IBI343, an antibody-drug conjugate, targets gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an early-stage investigational medicine. Takeda will lead global co-development and commercialization efforts outside Greater China and plans to establish US manufacturing for these medicines.
The agreement also includes a USD 1.2 billion upfront payment to Innovent, with additional milestones and royalties, subject to customary closing conditions.
The core Baker McKenzie team includes Randy Sunberg (Partner, New York), Devin Muntz (Associate, Chicago), Anat Polyachenko (Associate, New York) and Julia Rossié (Associate, Munich) on the licensing, option and collaboration agreement; Christina Lee (Partner, Hong Kong) and Brian Wong (Partner, Hong Kong) on share issuance agreement; and Creighton Macy (Partner, Washington, DC) and Daniel Duk-ki Moon (Associate, Washington, DC) on HSR/antitrust matters.
Learn more about the deal on the Takeda website.
With one of the largest Healthcare & Life Sciences groups of any international law firm, Baker McKenzie’s knowledge in the sector has been honed over more than six decades and rooted in the Firm’s corporate DNA. The Firm has deep industry acumen in more than 40 jurisdictions and key areas of law, including transactions, regulatory investigations and disputes.
